Palisade Bio Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.35 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.43Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $249.2M Enterprise Value $116.6M Shares Outstanding 167.4M diluted Next Earnings Date31 Dec 2027 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Palisade Bio, Inc. (NASDAQ: PALI) is a clinical-stage biopharmaceutical company that has successfully pivoted its pipeline toward next-generation, gut-targeted oral therapies. Following the termination of its legacy asset LB1148 due to a Phase 2 trial failure in 2023, the company has focused entirely on PALI-2108, a once-daily, gut-microbiota-activated PDE4 inhibitor prodrug designed for localized delivery to the terminal ileum and colon. This targeted approach minimizes systemic exposure, potentially overcoming the severe tolerability issues (such as nausea and headache) that have historically limited systemic PDE4 inhibitors. Backed by a massive capital infusion of $127.6 million in late 2025, Palisade Bio is exceptionally well-capitalized with $132.6 million in cash as of Q1 2026. This cash runway is projected to fund operations through major clinical milestones, including Phase 2 readouts for both Ulcerative Colitis (UC) and Fibrostenotic Crohn's Disease (FSCD) in late 2027 and early 2028, respectively. With a strong cash position, a highly differentiated platform, and upcoming Phase 2 IND submissions in 2026, Palisade Bio presents a compelling high-upside opportunity for biotechnology investors. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$5.00 Mean target$10.22 High · most bullish analyst$25.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The bear case reflects potential clinical or regulatory delays in clearing the Phase 2 INDs or slower-than-expected patient enrollment. If Phase 2 clinical data reveals unexpected safety signals, or if the localized bioactivation fails to achieve therapeutic concentrations in a larger patient cohort, the utility of the prodrug platform would be severely compromised. Given the company's single-asset focus, any failure of PALI-2108 would result in significant value destruction, forcing the company to seek alternative pipeline candidates or face liquidation. Base CaseCentral scenario The base case assumes Palisade Bio successfully submits and obtains FDA clearance for its Phase 2 IND applications for PALI-2108 in both UC and FSCD during 2026. Clinical trials progress on schedule, supported by the company's robust cash reserves of $132.6 million, which eliminates near-term dilution risk. The Phase 2 trials demonstrate that PALI-2108's localized bioactivation mechanism successfully delivers therapeutic efficacy in the colon while maintaining a superior safety and tolerability profile compared to systemic PDE4 inhibitors. Under this scenario, the stock is re-rated as it approaches its primary efficacy readouts in late 2027 and early 2028. Bull CaseUpside scenario Palisade Bio's bull case centers on its lead asset, PALI-2108, a microbiome-activated oral prodrug targeting PDE4 locally in the colon for inflammatory bowel disease (IBD). This localized approach aims to deliver the anti-inflammatory efficacy of PDE4 inhibition while avoiding the severe systemic side effects (such as nausea and neuropsychiatric events) that historically limited systemic PDE4 inhibitors. The thesis is supported by a strong balance sheet with approximately $130M to $133M in cash, providing a robust runway through 2029 to fully fund clinical trials (including the Phase 2 ASCENTRA-UC study in ulcerative colitis) without near-term dilution risk. Positive clinical readouts represent a major catalyst that could significantly re-rate the stock or position Palisade as an attractive acquisition target for major pharmaceutical companies active in the autoimmune space. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |